Preclinical evaluation of EPHX2 inhibition as a novel treatment for inflammatory bowel disease.

Preclinical evaluation of EPHX2 inhibition as a novel treatment for inflammatory bowel disease.

Epoxyeicosatrienoic acids (EETs) are signaling lipids produced by cytochrome P450 epoxygenation of arachidonic acid, which are metabolized by EPHX2 (epoxide hydrolase 2, alias soluble epoxide hydrolase or sEH). EETs have pleiotropic effects, including anti-inflammatory activity. Using a Connectivity...

Full description

Bibliographic Details
Main Authors: William C Reisdorf, Qing Xie, Xin Zeng, Wensheng Xie, Neetu Rajpal, Bao Hoang, Mark E Burgert, Vinod Kumar, Mark R Hurle, Deepak K Rajpal, Sarah O'Donnell, Thomas T MacDonald, Anna Vossenkämper, Lin Wang, Mike Reilly, Bart J Votta, Yolanda Sanchez, Pankaj Agarwal
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0215033

Internet

https://doi.org/10.1371/journal.pone.0215033

Similar Items